Application of punicalagin in preparing medicine for preventing and curing postmenopausal osteoporosis

Abstract

The invention discloses application of punicalagin in preparing the medicine for preventing and curing postmenopausal osteoporosis, and further discloses a pharmaceutic preparation for preventing andcuring postmenopausal osteoporosis. The therapeutic action of punicalagin (PUN) on osteoporosis of ovariectomized mice is observed by applying the ovariectomized mouse osteoporosis model, the changesof the key indicators, including RANKL and CTSK, of osteoclast activation are evaluated, various indexes of osteoporosis are analyzed, and then therapeutic action mechanism of PUN on estrogen deficiency osteoporosis can be explained. According to the therapeutic action mechanism, after menopause, because of estrogen deficiency, the expression of RANKL can be up-regulated by bone resorption factors, the RANKL path is activated, osteoclasts are activated as a result, and at present, the mechanism is the important one of causing postmenopausal osteoporosis; and the application of PUN is a new wayfor preventing and curing postmenopausal osteoporosis because PUN can inhibit the path and thereby inhibiting osteoclast activation.

Description

technical field [0001] The invention belongs to the technical field of new uses of chemical drugs, and specifically relates to the application of punicalagin in the preparation of drugs for preventing and treating postmenopausal osteoporosis. Background technique [0002] Postmenopausal osteoporosis (Postmenopausal Osteoporosis, PMO) is a common metabolic bone disease. It is due to the hyperactivity of osteoclasts and imbalance of bone metabolism caused by estrogen deficiency in postmenopausal women, resulting in decreased bone mass and poor bone tissue microstructure. Altered bone disease manifested by increased bone fragility and susceptibility to fracture. Osteoporosis has become the second most harmful and incurable chronic disease in the world after cardiovascular disease. According to statistics, postmenopausal osteoporosis affects more than 200 million women worldwide, and one-third of women over the age of 50 will experience osteoporotic fractures, which brings grea...

AI Technical Summary

Problems solved by technology

[0008] In the past, it was reported that PUN alone could inhibit the differentiation of RAW264. The prevention and treatment effect of osteoporosis is not ideal

[0009] At present, there is no effective drug treatment for postmenopausal osteoporosis (PMO), and there is no report on the prevention and treatment of PMO by PUN, and the present invention comes from this

Images